Partner prior second look in Couch way too risky for big pharma x to let y grab what might be. Does anyone think J and J said let's wait for more data on ibrutinib it's only in phase II and only been studied on less then 200 patient. Yeah more data is what Peregrine needs to show???? We have too much data. Now we have human data for upstream down stream. A deal is coming. It's all coming down to the art of the deal! http://seekingalpha.com/article/3657006-peregrine-pharmaceuticals-the-art-of-the-deal
Market Data 
Markets
AI
